Actinium Pharmaceuticals, Inc. (ATNM) Year-over-year earnings per share growth for the last twelve months

Actinium Pharmaceuticals (ATNM) - corporate logo

Actinium Pharmaceuticals' experienced management effectively attracts investment while ensuring transparent interaction with the FDA. The shift in quarterly EPS reflects profit dynamics, with the metric holding around -12.90 despite geopolitical risks and logistical disruptions in radiopharmaceutical supplies. High production costs and patent protection create insurmountable barriers for new entrants in the blood cancer treatment sector.

actiniumpharma.com (ATNM) - Year-over-year earnings per share growth for the last 12 months from 07/04/2022 to 11/18/2026

Analytical breakdowns and data insights for company Actinium Pharmaceuticals, Inc. (ATNM)

- market value and analyst target forecast:
Fundamental company valuation:Actinium Corp - ATNM
Flagship merchandise of actiniumpharma.com

Actinium Pharmaceuticals (ATNM) is implementing robotic systems for the synthesis of radiopharmaceuticals, minimizing manual labor and personnel risks during the production of blood cancer medications. The quarterly EPS growth rate measures the dynamics of net profit per share, allowing investors to filter out market noise and assess the real fundamental earnings trend to avoid overpaying for the asset at an inflated valuation.

Competitors of Actinium Pharmaceuticals (ATNM)

tgtherapeutics.com (TGTX) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Arcellx Therapeutics (ACLX)|Year-over-year earnings per share growth for the last twelve months Disc Medicine Inc|Earnings per share growth in annualized terms for the last twelve months Syndax Pharmaceuticals SNDX|Quarterly EPS earnings growth KURA|ADC Therapeutics SA - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth FHTX (Foghorn Therapeutics, Inc.)|Vor Bio Inc. (VOR) - Earnings per share growth in annualized terms for the last twelve months|NKTX - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months coeptistx.com|ESLA (Estrella Immunopharma) - Year-over-year net earnings per share growth for the last 12 months|CASI - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Marker Bio|Quarterly EPS earnings growth IN8bio, Inc.|Year-over-year earnings per share growth for the last twelve months Eterna Therapeutics Inc (ERNA)|Year-over-year net earnings per share change for the last twelve months gtbiopharma.com|Quarterly EPS earnings growth APTO (Aptose Biosciences)|Quarterly EPS earnings growth Bio-Path BPTH|MEI Pharma Inc - Quarterly EPS earnings growth|VINC (Vincerx Pharma Inc.) - Year-over-year earnings per share growth for the last 12 months